The combination demonstrated a tolerable safety profile, as per the trial’s preliminary data involving 16 subjects.

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive ...

Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) announced preliminary data from the ongoing Phase 1b portion of the ...

Jaguar Health (JAGX)family company Napo Pharmaceuticals provided an overview of the data from the poster presentation conducted yesterday, ...

The findings revealed that the combination of Aabemaciclib 150 mg twice daily with the recommended Phase 3 monotherapy dose of 200 mg of Vepdegestrant once daily was safe and well-tolerated in the ...